Hypoxia-inducible factors HIF-1α and HIF-2α expression in bladder cancer and their associations with other angiogenesis-related proteins

Urologia Internationalis

Volumn 77, Issue 3, 2006, Pages 255-263

  Ioachim, E ^a,d   Michael, M ^a   Salmas, M ^c   Michael, M M ^c   Stavropoulos, N E ^b   Malamou Mitsi, V ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b G HATZIKOSTA GENERAL HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

^d UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Bladder cancer; Extracellular matrix components; Hypoxia inducible factors (HIF 1 , HIF 2 ); Immunohistochemistry; Thymidine phosphorylase; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS RELATED PROTEIN; BIOLOGICAL MARKER; FIBRONECTIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; PROTEIN; PROTEIN BCL 2; PROTEIN P53; TENASCIN; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER RECURRENCE; CARCINOMA IN SITU; CLINICAL FEATURE; CORRELATION ANALYSIS; DENSITY; DISEASE MARKER; EXTRACELLULAR MATRIX; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; STROMA; TRANSCRIPTION INITIATION; TUMOR CELL; TUMOR DIFFERENTIATION; TUMOR VASCULARIZATION; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BIOPSY; CYTOPLASM; DISEASE PROGRESSION; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STROMAL CELLS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33750028186     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094819     Document Type: Article

References (50)

1. Fandrey J: Hypoxia-inducible gene expression. Respir Physiol 1995;101:1-10.
2. Harris AL: Hypoxia: a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
3. Semenza GL, Wang GL: A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992;12:5447-5454.
4. 2 tension. Proc Natl Acad Sci USA 1995;92:5510-5514.
5. Semenza GL: Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 2002;64:993-998.
6. Tian H, McKnight SL, Russell DW: Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997;11:72-82.
7. Wenger RH and Gassmann M: Oxygen(es) and hypoxia-inducible factor-1. Biol Chem 1997;378:609-616.
8. Jones A, Fujiyama C, Blance C, Moore JW, Fuggle S, Cranston D, Bicknell R, Harris AL: Relation of vascular endothelial growth factor production to expression and regulation of hypoxia-inducible factor-1 alpha and hypoxia-inducible factor-2 alpha in human bladder tumors and cell lines. Clin Cancer Res 2001;7:1263-1272.
9. Ishikawa F, Miyazono K, Hellman U, et al: Identification of angiogenic activity and the cloning and expression of the platelet-derived endothelial cell growth factor. Nature 1989;338:557-562.
10. Jones A, Fujiyama C, Turner K Cranston D, Stratford I, Bicknell R, et al: Role of thymidine phosphorylase in an in vitro model of human bladder cancer invasion. J Urol 2002;60:6298-6302.
11. Chiquet-Ehrismann R, Kalla P, Pearson CA, Beck K, Chiquet M: Tenascin interferes with fibronectin action. Cell 1988;53:383-390.
12. George EL, Baldwin HS, Hynes RO: Fibronectins are essential for heart and blood vessel morphogenesis but are dispensable for initial specification of precursor cells. Blood 1997;90:3073-3081.
13. Bowersox JC, Sorgente N: Chemotaxis of aortic endothelial cell in response to fibronectin. Cancer Res 1982;42:2547-2551.
14. Madri JA, Pratt BM, Tucker AM: Phenotypic modulation of endothelial cell by transforming growth factor-b depends upon the composition of the extracellular matrix. J Cell Biol 1988;106:1375-1384.
15. Nicosia RF, Bonnano E, Smith M: Fibronectin promotes the elongation of microvessels during angiogenesis in vitro. J Cell Physiol 1993;154:654-661.
16. Epstein JI, Amin MB, Reuter VR, Nostofi FK: The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998;22:1435-1448.
17. Stavropoulos NE, Hastazeris K, Filiadis I, Mihailidis I, Ioachim E, Liamis Z, Kalomiris P: Intravesical instillations of interferon gamma in the prophylaxis of high risk superficial bladder cancer: results of a controlled prospective study. Scand J Urol Nephrol 2002;36:218-222.
18. Theodoropoulos VE, Lazaris AC, Sofras F, Gerzelis I, Tsoukala V, Ghikonti I, Manikas K, Kastriotis I: Hypoxia-inducible factor 1α expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol 2004;46:200-208.
19. Theodoropoulos V, Lazaris A, Kastriotis I Spiliadi C, Theodoropoulos G, Tsoukala V, Patsouris E, Sofras F: Evaluation of hypoxia-inducible factor 1α overexpession as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. BJU 2005;95:425-431.
20. Stavropoulos NE, Bouropoulos C, Ioachim EI, Michael M, Hastazeris K, Tsimaris I, Kalogeras D, Liamis Z, Stefanaki S, Agnantis NI: Prognostic significance of angiogenesis in superficial bladder cancer. Int Urol Nephrol 2004;36:163-167.
21. Ioachim E, Michael M, Stavropoulos NE, Kitsiou E, Hastazeris K, Salmas M, Stefanaki S, Agnantis NJ: Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21(Waf1/Cip1) and p27(Kip1) in urothelial carcinoma: correlation with other cell cycle related proteins (Rb, p53, Ki-67 and PCNA) and clinicopathological features. Urol Int 2004;73:65-73.
22. Ioachim E, Michael M, Stavropoulos NE, Ioachim E, Michael M, Stavropoulos NE, Kitsiou E, Salmas M, Malamou-Mitsi B: A clinicopathological study of the expression of extracellular matrix components in urothelial carcinoma. Br J Urol 2005;95:655-659.
23. Birner P, Gatterbauer B, Oberhuber G Schindl M, Rossler K, Prodinger A, Budka H, Hainfellner JA: Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer 2001;92:165-171.
24. Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P, Oberhuber G: Overexpression of hypoxia-inducible factor 1 alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 2002;8:1831-1837.
25. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G: Overexpression of hypoxia-inducible factor 1 alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000;60:4693-4696.
26. Haugland HK, Vukovic V, Pintilie M, Fyles AW, Milosevic M, Hill RP, Hedley DW: Expression of hypoxia-inducible factor-1alpha in cervical carcinomas: correlation with tumor oxygnation. Int J Radiat Oncol Biol Phys 2002;53:854-861.
27. Beasley NJ, Leek R, Alam M, Turley H, Cox GJ, Gatter K, Millard P, Fuggle S, Harris AL: Hypoxia inducible factors HIF-1 alpha and HIF-2 alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically rejected patients. Cancer Res 2002;62:2493-2497.
28. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos C, Turley H, Talks K, Gatter KC, Harris AL: Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;53:1192-1202.
29. Onita T, Guang P, Xuan JW, Sakai H, Kanetake H, Maxwell PH, Fong G-H, Gabril MY, Moussa M, Chin JL: Hypoxia-induced, perinecrotic expression of endothelial Per-ARNT-Sim domain protein-1/hypoxia-inducible factor-2α correlates with tumor progression, vascularization, and focal macrophage infiltration in bladder cancer. Clin Cancer Res 2002;8:471-480.
30. Ji P, Xuan JW, Onita T, Sakai H, Kanetake H, Gabril MY, Sun Y, Moussa M, Chin JL: Correlation study showing no concordance between EPAS/HIF-2α mRNA and protein expression in transitional cell cancer of the bladder. Urol 2003;61:851-857.
31. Crew JP, O'Brien T, Bicknell R, Fuggle S, Cranston D, Harris A: Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrences rates. J Urol 1999;161:799-804.
32. Chow NH, Liu HS, Chan SH, Cheng HL, Tzai TS: Expression of vascular endothelial growth factor in primary superficial bladder cancer. Cancer Res 1999;19:4593-4597.
33. Stavropoulos NE, Bouropoulos K, Ioachim E, Michael M, Hastazeris K, Tsimaris I, Kalogeras D, Liamis Z, Stefanaki S, Agnantis NJ: Prognostic significance of angiogenesis in superficial bladder cancer. Int Urol Nephrol 2004;36:163-167.
34. Berra E, Pages G, Pouyssegur J: MAP kinases and hypoxia in the control of VEGF expression. Cancer Metastasis Rev 2000;19:139-145.
35. Giatromanolaki A, Koukourakis MI, Sivridis E Turley H, Talks K, Pezzella F, Gatter KC, Harris AL: Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 2001;14:881-890.
36. Sivridis E, Giatromanolaki A, Gatter K, Harris A, Koukourakis M: Association of hypoxia-inducible factors 1α and 2α with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 2002;95:1055-1063.
37. Giatromanolaki A, Sivridis E, Kouskoukis C, Gatter KC, Harris AL, Koukourakis MI: Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res 2003;13:493-501.
38. Jiang C, Fan L, Liu Z, Qian Q, Xia D, Diao L, He Y, Ai Z: Expression levels and significance of hypoxia inducible factor-1 alpha and vascular endothelial growth factor in human colorectal adenocarcinoma. Chin Med J (Engl) 2004;117:1541-1546.
39. Huang G-W, Yang L-Y, Lu W-Q: Expression of hypoxia-inducible factor 1α and vascular endothelial growth factor in hepatocellular carcinoma: Impact on neovascularization and survival. World J Gastroenterol 2005;11:1705-1708.
40. Luo J, Peng ZL, Yang KX Wang H, Yang H, Dong DD, Yao XY: Relation between the expression of hypoxia inducible factor-1alpha and angiogenesis in ovarian cancer using tissue microarray (in Chinese). Zhonghua Fu Cha Ke Za Zhi 2005;40:38-41.
41. Kubota Y, Miura T, Moriyama M, Noguchi S, Matsuzaki J, Takebayashi S, et al: Thymidine phosphorylase activity in human bladder cancer: difference between superficial and invasive cancer. Clin Cancer Res 1997;3:973-976.
42. Mizutani Y, Okada Y, Yoshida O: Expression of platelet-derived endothelial cell growth factor in bladder carcinoma. Cancer 1997;79:1190-1194.
43. Arima J-I, Imazono Y, Takebayashi Y, Nishiyama K, Shirahama T, Akiba S, Furukawa T, Akiyama AI, Ohi Y: Expression of thymidine phosphorylase as an indicator of poor prognosis for patients with transitional cell carcinoma of the bladder. Cancer 2000;88:1131-1138.
44. Griffiths L, Dachs GU, Bicknell R Harris AL, Stanford IJ: The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo. Cancer Res 1997;57:570-572.
45. Kitazono M, Takebayashi Y, Ishitsuka K, Takao S, Tani A, Furukawa T, Miyadera K, Yamada Y, Aikou T, Akiyama S: Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase. Biochem Biophys Res Commun 1998;253:797-803.
46. Ikeda R, Furukama T, Kitazono M Ishitsuka K, Okumura H, Tani A, Sumizawa T, Haraguchi M, Komatsu M, Uchimiya H, Ren X-Q, Motoya T, Yamada K, Akiyama S-I: Molecular basis for the inhibition of hypoxia-induced apoptosis by 2-deoxy-d-ribose. Biochem Biophys Res Commun 2002;291:806-812.
47. Suzuki H, Omida A, Tsuruo T: Dephosphorylated hypoxia-inducible factor 1 alpha as a mediator of p53-dependent apoptosis during hypoxia. Oncogene 2001;20:5779-5788.
48. Blagosklonny MV, An WG, Romanova LY, Trepel J, Fojo T, Neckers L: p53 inhibits hypoxia-inducible factor-stimulated transcription. J Biol Chem 1998;273:11995-11998.
49. Acker T, Diez-Juan A, Aragones J, Tjwa M, Brusselmans K, Moons L, Fukumura D, Moreno-Murciano MP, Herbert JM, Burger A, Riedel J, Elvert G, Flamme I, Maxwell PH, Collen D, Dewerchim M, Jain RK, Plate KH, Garmeliet P: Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell 2005;8:131-141.
50. Sutton AB, Canfield AE, Schor SL Grant ME, Schor AM: The response of endothelial cells to TGFβ-1 is dependent upon cell shape, proliferative state and the nature of the substratum. J Cell Sci 1991;99:777-787.